TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 163 full-time employees. The company went IPO on 2024-08-20. The firm is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.
02410.HK stock price ended at $12.8 on 金曜日, after rising 1.03%
On the latest trading day Feb 13, 2026, the stock price of 02410.HK rose by 1.03%, climbing from $12.60 to $12.80. During the session, the stock saw a volatility of 2.38%, with prices oscillating between a daily low of $12.58 and a high of $12.88. Notably, trading volume dropped by 86.9K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.1M shares were traded, equating to a market value of approximately $4.8B.